Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

Share Price is delayed by 15 minutes
Get Live Data
936.00    0.00 (0.00%)
Bid:
932.00
Ask:
942.00
Spread: 10.00 (1.073%)
Market Cap: £256.19m
GHH Live PriceLast checked at - London Stock Exchange

Intraday Gooch & Housego Share Chart

Full Year Trading Update

4 Oct 2017 07:00

RNS Number : 6174S
Gooch & Housego PLC
04 October 2017
 

For immediate release

4 October 2017

 

 

Gooch & Housego PLC

("G&H" or the "Company")

 

Full Year Trading Update

 

"Trading in line with expectations"

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of optical components & systems, today announces that trading for the year ended 30 September 2017 is in line with its previous guidance. The Company expects to announce its audited results for the year ended 30 September 2017 on 28 November 2017.

During the financial year ended 30 September 2017, the business has benefited from positive market conditions and strong demand in its industrial and telecommunications sectors, in particular critical components used in microelectronic manufacturing and high reliability undersea fibre couplers.

 

G&H has started its new financial year with a record year end order book, which, as at 30 September 2017, stood at £72.2 million, an increase of 36.7% compared with the same time last year. Excluding the impact of foreign exchange and acquisitions this represents an increase of 29.2% on the starting order book last year.

 

Approximately one third of our business now relates to the Aerospace & Defence ("A&D") sector, due in part to the acquisitions made in FY 2016 and FY 2017.

 

In February 2017 the Company acquired StingRay Optics LLC ("StingRay"), a USA based specialist designer and manufacturer of high performance optical and opto-mechanical sub-systems for demanding defence and commercial applications. StingRay has integrated well into the wider business and has performed strongly since acquisition, contributing positively to the overall results of G&H in FY 2017.

 

Our performance improvement programme has made positive progress. There has been continued benefit from concentrating our Research and Development ("R&D") efforts on fewer higher return projects and from enhanced business development activity. We have invested in our skills base, the latest manufacturing equipment, improved lean processes and business systems and we intend to continue to do so in order to support our future growth.

The Company remains in a strong financial position and will make further investment in the business.

Mark Webster, Chief Executive Officer of Gooch & Housego, commented:

"G&H is well positioned to take advantage of the positive market conditions and we continue to invest in people, processes, systems and capital equipment to meet the demands of a robust order book.

"We remain committed to further diversification of the business and moving up the value chain. This has been most evident in the A&D sector, where recent acquisitions and investment in R&D has taken us closer to establishing 'critical mass' in this sector.

"We will continue to invest in our performance improvement plan which we believe will underpin our future growth."

 

 

For further information contact: -

 

Mark Webster / Andrew Boteler

Gooch & Housego PLC

01460 256440

Mark Court / Sophie Cowles

Buchanan

020 7466 5000

Patrick Robb / David Anderson

Investec Bank plc

020 7597 5970

 

 

 

 

 

 

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFSAFADFWSEIS
Date   Source Headline
9th May 20197:00 amRNSNotification of Half Year Results
30th Apr 20197:00 amRNSAppointment of Chief Financial Officer
9th Apr 20197:00 amRNSCapital Markets Day
9th Apr 20197:00 amRNSHalf Year Trading Update
28th Mar 20195:28 pmRNSDirector/PDMR Shareholding
28th Mar 20195:25 pmRNSDirector/PDMR Shareholding
28th Mar 20195:24 pmRNSDirector/PDMR Shareholding
25th Mar 20195:24 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSITL signs manufacturing agreement with OrganOx
25th Feb 201911:27 amRNSDirector Share Purchase
21st Feb 20192:58 pmRNSDirector Share Purchase
20th Feb 20191:07 pmRNSResult of AGM
20th Feb 20197:00 amRNSAGM Trading Update
9th Jan 201910:17 amRNSGrant of LTIP Awards
9th Jan 20197:00 amRNSSite Visit to ITL Life Science Business
28th Dec 201811:14 amRNSBlock Listing Six Monthly Return
28th Dec 201811:13 amRNSIssue of Equity and Total Voting Rights
28th Dec 201811:12 amRNSBlock Listing Application
11th Dec 20184:44 pmRNSAdditional Listing
11th Dec 20187:00 amRNSPosting of Annual Report and AGM Notice
5th Dec 201811:30 amRNSDirector/PDMR Shareholding
5th Dec 201811:28 amRNSDirector/PDMR Shareholding
27th Nov 201811:36 amRNSDirector/PDMR Shareholding
27th Nov 20187:00 amRNSCFO Succession
27th Nov 20187:00 amRNSPreliminary Results
30th Oct 201811:06 amRNSHolding(s) in Company
29th Oct 201811:08 amRNSHolding(s) in Company
25th Oct 20184:40 pmRNSHolding(s) in Company
25th Oct 20187:00 amRNSNotification of Preliminary Results
23rd Oct 201810:23 amRNSHolding(s) in Company
4th Oct 20187:00 amRNSFull Year Trading Update
26th Sep 20189:00 amRNSHolding(s) in Company
6th Sep 20187:00 amRNSAerospace and Defence Acquisition
8th Aug 20187:00 amRNSLife Sciences Acquisition
12th Jul 20189:26 amRNSHolding(s) in Company
13th Jun 201810:08 amRNSHolding(s) in Company
6th Jun 20182:02 pmRNSDirector/PDMR Shareholding
5th Jun 20187:00 amRNSInterim Results
3rd May 20187:00 amRNSNotification of Half Year Results
6th Apr 20187:00 amRNSHalf Year Trading Update
3rd Apr 20184:35 pmRNSPrice Monitoring Extension
20th Mar 20188:25 amRNSHolding(s) in Company
21st Feb 20185:20 pmRNSResult of AGM
21st Feb 20187:00 amRNSAGM Trading Update
22nd Jan 20181:00 pmRNSDirector/PDMR shareholding
22nd Jan 20181:00 pmRNSDirector/PDMR shareholding
22nd Jan 20181:00 pmRNSDirector/PDMR shareholding
22nd Jan 20181:00 pmRNSDirector/PDMR shareholding
18th Jan 20181:35 pmRNSGrant of LTIP Awards
22nd Dec 20179:13 amRNSBlock Listing Application

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.